Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Comparison Tests01:13

Multiple Comparison Tests

3.9K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
3.9K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

62
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
62
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

768
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
768

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Orolabial and Genital Herpes Clinical Trials: A Meta-analysis of Endpoints.

Open forum infectious diseases·2026
Same author

Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses.

Experimental dermatology·2024
Same author

Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo.

Archives of dermatological research·2024
Same author

A repeated measures approach to pooled and calibrated biomarker data.

Biometrics·2021
Same author

Design and analysis considerations for combining data from multiple biomarker studies.

Statistics in medicine·2018
Same author

Ultrastructural study on human placentae from women subjected to assisted reproductive technology treatments.

Biology of reproduction·2011
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.6K

Combination MCP-Mod for two-drug combination dose-ranging studies.

Yifan Zhou1, Abigail Sloan1, Sandeep Menon1

  • 1Pfizer Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.

Journal of Biopharmaceutical Statistics
|February 9, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces Combination MCP-Mod, a new method for optimizing two-drug combination therapies. It efficiently identifies optimal doses, improving drug development timelines and efficacy in clinical trials.

Keywords:
MCP-Modcombination therapydose-findingdose-responseproof of concepttarget dose

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.6K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

Related Experiment Videos

Last Updated: Jul 4, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.6K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.6K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

Area of Science:

  • Biostatistics
  • Pharmacometrics
  • Clinical Trial Design

Background:

  • Combination therapies offer enhanced efficacy and safety over single agents.
  • Optimizing doses for two-drug combinations is complex, often requiring large sample sizes and lengthy studies.
  • Current methods like full factorial designs can be inefficient for dose-finding.

Purpose of the Study:

  • To extend the MCP-Mod methodology to a three-dimensional space for modeling two-drug combination dose-response surfaces.
  • To develop a framework (Comb MCP-Mod) for selecting optimal combination doses for pivotal clinical studies.
  • To provide guidance on power and sample size calculations for study designs using Comb MCP-Mod.

Main Methods:

  • Extension of the MCP-Mod design to a 3D space to model the dose-response surface of two-drug combinations.
  • Development of a contrast test statistic for selecting the best dose-response model.
  • Formulation of power and sample size calculation guidance for study design.

Main Results:

  • Comb MCP-Mod effectively models the dose-response surface for two-drug combinations.
  • The method provides a set of optimal dosages for each drug to achieve a target response.
  • Simulation studies confirmed Comb MCP-Mod's performance in controlling error rates and detecting dose-response relationships.

Conclusions:

  • Comb MCP-Mod offers a statistically sound and efficient approach for optimizing two-drug combination therapies.
  • This method can lead to more powerful detection of dose-response relationships compared to traditional approaches.
  • The framework aids in selecting optimal doses for pivotal studies, potentially shortening development timelines.